Related Experiment Video
Updated: Jun 17, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
[Studies of gene therapy for Parkinson's disease]
1Department of Neurology, Kitasato University.
Abstract:
Currently, four Phase I clinical trials are underway utilizing recombinant adeno-associated viral (rAAV) vectors for the treatment of Parkinson's disease. The vehicle used mainly for gene delivery to the human brain is rAAV vector, which is non-pathogenic and non-self-amplifying. At present, the gene therapy approach is not the best way for the treatment of PD patients, but we believe that the further progress is anticipated toward making this strategy a therapeutic option for PD in the future. This article will review currently ongoing clinical trials of PD gene therapy and then introduce our studies about the gene therapy for PD.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Gene Therapy
Gene Therapy
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
